Stock Market Reviews

KURA (Kura Oncology, Inc.) News

Get the latest news, insights, and market updates on KURA (Kura Oncology, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Kura and Kyowa Kirin secure FDA go-ahead for targeted leukaemia therapy
  Komzifti now becomes the first once-daily targeted therapy for r/r AML, though it will have to fight Syndax’s Revuforj for market share.
  Nov 14, 2025 - $KURA
• Lundbeck sparks bidding war with Alkermes; Pfizer closes Metsera deal
  Pfizer quickly consummated the $10 billion buyout after one-upping Novo Nordisk. Elsewhere, Lundbeck submitted a rival offer for Avadel Pharmaceuticals and Zealand Pharma dropped an obesity drug.
  Nov 14, 2025 - $KURA
• Kura Oncology and Kyowa Kirin Announce FDA Approval of KOMZIFTI™ (ziftomenib), the First and Only Once-Daily Targeted Therapy for Adults with Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia
  – NPM1 mutations, one of the most common genetic drivers of AML, are now actionable for patients – – Acute unmet need in R/R NPM1-mutated AML defined by historically poor outcomes and low survival rates at relapse – – FDA grants full approval of KOMZIFTI ahead of PDUFA target action date – – Approval is based on the KOMET-001 trial, in which KOMZIFTI demonstrated deep responses, a potentially best-in-class safety profile, once-daily administration, and ease of co-administration with common suppo
  Nov 13, 2025 - $KURA
• Kura Oncology to Participate in Upcoming Investor Conference
  SAN DIEGO, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the following investor conference: Jefferies Global Healthcare ConferenceNovember 19, 20253:30 p.m. GMT / 10:30 a.m. ET / 7:30 a.m. PT A live audio webcast will be available in the Investors section of Kura’s website at https://kuraoncology.com/, with
  Nov 12, 2025 - $KURA
• How Recent Events Are Rewriting the Story for Kura Oncology
  Kura Oncology’s consensus analyst price target has nudged upward, rising from $27.00 to $27.18 following new coverage and insight into the company’s outlook. This minor revision signals a cautiously optimistic tone as analysts weigh the potential of Kura’s oncology pipeline against ongoing questions around competition and execution risks. Stay tuned to discover how investors can monitor these narrative shifts and remain informed about further developments surrounding Kura Oncology. Stay...
  Nov 7, 2025 - $KURA
• Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  SAN DIEGO, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on November 3, 2025, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 21,750 shares of common stock to a new non-executive emplo
  Nov 7, 2025 - $KURA
• Kura Oncology (KURA): Persistent Losses Undercut Rapid 42.7% Revenue Growth Narrative
  Kura Oncology (KURA) is forecast to grow revenue at 42.7% per year, far outpacing the US market average of 10.5% per year. However, the company remains unprofitable with losses increasing at a 15.3% annual rate over the past five years. Despite this high growth outlook, profit margins have not improved and analysts expect losses to continue over the next three years. Investors face a classic trade-off here: rapid revenue growth against persistent losses and profitability concerns. See our...
  Nov 5, 2025 - $KURA
• Kura Oncology Inc (KURA) Q3 2025 Earnings Call Highlights: Strategic Advances Amid Rising Expenses
  Kura Oncology Inc (KURA) reports significant revenue growth and strategic progress in clinical trials, despite increased expenses and net loss.
  Nov 4, 2025 - $KURA
• Kura Oncology (KURA) Reports Q3 Loss, Lags Revenue Estimates
  Kura Oncology (KURA) delivered earnings and revenue surprises of -49.12% and -75.72%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
  Nov 4, 2025 - $KURA
• Kura Oncology: Q3 Earnings Snapshot
  SAN DIEGO (AP) — Kura Oncology Inc. KURA) on Tuesday reported a loss of $74.1 million in its third quarter. On a per-share basis, the San Diego-based company said it had a loss of 85 cents.
  Nov 4, 2025 - $KURA